drugset
drugset / Trial / NCT05044325

A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants

NCT05044325 ↗

Phase 1 Terminated 27 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This will be a FTIH study which aims to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of GSK3884464 administered to healthy participants.

Timeline

Start
2021-09-20
Primary completion
2022-08-05
Completion
2022-08-05

Outcome

Outcome not reported

Stopped: “To allow for additional assessments from supplementary non-clinical activities.”

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK3884464 Unknown 1 mg Oral
Subject GSK3884464 Unknown 3 mg Oral
Subject GSK3884464 Unknown 9 mg Oral
Subject GSK3884464 Unknown 15 mg Oral
Subject GSK3884464 Unknown 30 mg Oral
Subject GSK3884464 Unknown 70 mg Oral
Subject GSK3884464 Unknown 110 mg Oral

Indications

heart failure